Nathaniel Moore, MD
Family Medicine · Denver, CONPI 1275570301
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,309 of the $1,571 with a category attached, or 83.3%. It is spread thinly across 25 manufacturers, the largest accounting for just 18.7% — the pattern of someone who eats at a lot of different presentations.
Across 66 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Titan Pharmaceuticals, Inc.$294
- Johnson & Johnson$131
- Indivior Inc.$120
- Alkermes, Inc.$110
- Merck$106
- Pfizer$89
- plus $721 from 19 others
Across 1 payment — averaging $19,050 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$19K
What the payments were for
- Consulting fees$25016%
- Food & beverage$1,30983%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Titan Pharmaceuticals, Inc. | 4 | $294 |
| Johnson & Johnson | 1 | $131 |
| Indivior Inc. | 6 | $120 |
| Alkermes, Inc. | 6 | $110 |
| Merck | 6 | $106 |
| Pfizer | 4 | $89 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $71 |
| Astellas Pharma US Inc | 3 | $69 |
| Lilly USA, LLC | 3 | $59 |
| Boehringer Ingelheim | 3 | $46 |
| AstraZeneca | 3 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Aimmune Therapeutics, Inc. | 3 | $43 |
| Amgen | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $39 |
| Amarin Pharma, Inc. | 1 | $38 |
| Eisai Inc. | 2 | $35 |
| Viiv Healthcare Company | 1 | $32 |
| Orexo US, Inc. | 2 | $31 |
| USWM, LLC | 2 | $30 |
| Hologic Sales And Service, LLC | 2 | $29 |
| Braeburn Inc. | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Exeltis, USA Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Probuphine$250
- Monarch Platform$131
How this compares
$1,571 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 73 | $104,650 |
| MounjaroTirzepatide | 44 | $65,004 |
| JardianceEmpagliflozin | 39 | $42,803 |
| FarxigaDapagliflozin Propanediol | 34 | $40,105 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 161 | $35,673 |
| GlatopaGlatiramer Acetate | 12 | $32,758 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 100 | $31,208 |
| EliquisApixaban | 20 | $26,266 |
| TrulicityDulaglutide | 18 | $21,748 |
| NucyntaTapentadol Hcl | 18 | $21,096 |
| RexultiBrexpiprazole | 11 | $18,711 |
| Spiriva RespimatTiotropium Bromide | 18 | $16,686 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $16,543 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 120 | $8,358 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $7,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $16 | $104,65073 claims |
| Lilly USA, LLCMounjaro, Trulicity | $59 | $86,75262 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $46 | $59,48957 claims |
| AstraZenecaFarxiga, Symbicort | $44 | $44,63147 claims |
| PfizerEliquis | $89 | $26,26620 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $44 | $18,71111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Denver
- Ethan LazarusDenver$688K
- Mark DeutchmanDenver$258K
- Mia ScottDenver$53K
- Flory KreutterDenver$13K
- Khoi NguyenDenver$13K
- Michael de NardisLarkspur$335K
- Matthew YoungColorado Springs$270K
- Kari UusinarkausWoodland Park$254K
- Michael MeekerUsaf Academy$174K
- Carolynn Francavilla BrownLakewood$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.